<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761371</url>
  </required_header>
  <id_info>
    <org_study_id>1456-IMIQ</org_study_id>
    <secondary_id>X-03016-9359000001</secondary_id>
    <nct_id>NCT00761371</nct_id>
  </id_info>
  <brief_title>Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients</brief_title>
  <official_title>Exploratory Evaluation of Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Treated With HAART (CD4+ ≥ 200 Cells mm3): An Open Labeled, Non-comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORION Sante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      Imiquimod 5% cream in the treatment of external genital or perianal warts in HIV+ patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the percentage of HIV+ subjects successfully treated with HAART, with total
      clearance (100%) of baseline external genital or perianal warts within 16 weeks of treatment
      with imiquimod 5% cream.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects with total clearance of initially treated external genital or perianal warts.</measure>
    <time_frame>week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a partial reduction of initial wart area;</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve reduction in wart area;</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in wart number</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance of new warts</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV DNA</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ lymphocyte and HIV RNA levels</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Warts</condition>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imiquimod 5% cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5% cream</intervention_name>
    <description>Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.</description>
    <arm_group_label>Imiquimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject able to understand and willing to give written informed consent.

          2. Subject ≥ 18 and &lt; 70 years of age.

          3. Male or female with an HIV infection documented by serology (enzyme linked
             immunoabsorbent assay (ELISA)), Western Blot assay, or HIV viral load.

          4. Treated with HAART for at least six months and compliant with the treatment.

          5. Evidence of efficacy of HAART: total CD4+ lymphocyte counts of ≥ 200 cells/mm3 AND
             plasma HIV RNA level &lt; 104 RNA copies/mL within four weeks prior to the Treatment
             Initiation Visit.

          6. Presence of at least one visible genital or perianal wart as determined by clinical
             diagnosis.

          7. Total wart area &gt; 10 mm2 and ≤ 4000 mm2 (diameter &gt; 0.4 cm and ≤ 7.1 cm)

          8. Karnofsky Performance Status ≥ 70 %.

          9. Accepting to abstain from sexual intercourse when study drug is on the skin.

         10. In case of a coexisting AIDS-defining illness, both this illness and any treatment
             being received for it must have been stable for the four weeks preceding enrolment in
             the trial.

         11. If female and of childbearing potential, have negative urine pregnancy tests, and
             willing to use a medically acceptable method of contraception during the 16-week
             treatment period. Subjects were considered to be of childbearing potential unless the
             uterus or both ovaries had been removed or they were two or more years postmenopausal.
             For this study, the following were considered to be acceptable methods of
             contraception:

               -  Surgical sterilization, defined as tubal ligation of the subject or a vasectomy
                  of the subject's partner if that subject is in a monogamous heterosexual
                  relationship (at the Investigator's discretion)

               -  Oral, injectable, or implantable contraceptives

               -  Condoms (with spermicide)

               -  Diaphragm/cervical cap (with spermicide)

               -  Intrauterine devices (IUDs)

               -  Complete abstinence (at the Investigator's discretion)

        Exclusion Criteria:

          1. Women pregnant or lactating;

          2. Treatment within four weeks prior to the Treatment Initiation Visit and throughout the
             entire study with:

               -  Any genital wart therapy, or Immunomodulators

               -  Systemic antiviral drugs other than acyclovir, valacyclovir, or famcyclovir and
                  other than HAART
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Saiag, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ambroise Pare, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Départment de Gynécologie-Obstétrique CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service Dermatologie C.H. François Rabelais (César de Paepe)</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie et Vénéréologie Hôpital Saint Jacques</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>F-25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Bordeaux</city>
        <zip>F-33800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie, Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>F-92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Maladies Infectieuses Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>F-13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>F-44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Hôpital de l'Archet II</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service Dermatologie Hopital COCHIN - Pavillon Tarnier</name>
      <address>
        <city>Paris</city>
        <zip>F-75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Paris</city>
        <zip>F-75011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Alfred Fournier</name>
      <address>
        <city>Paris</city>
        <zip>F-75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Paris</city>
        <zip>F-75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Groupe Hospitalier Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>F-75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>F-75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Groupe Hospitalier La Grave</name>
      <address>
        <city>Toulouse</city>
        <zip>F-31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie Centre Hospitalier de Valence</name>
      <address>
        <city>Valence</city>
        <zip>F-26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <name_title>Joachim Maus, MD / Director, Clinical Development</name_title>
    <organization>Meda Pharma GmbH &amp; Co. KG</organization>
  </responsible_party>
  <keyword>external genital and perianal warts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

